Skip navigation
  • Home
  • Browse
    • Communities
      & Collections
    • Browse Items by:
    • Publication Date
    • Author
    • Title
    • Subject
    • Department
  • Sign on to:
    • My MacSphere
    • Receive email
      updates
    • Edit Profile


McMaster University Home Page
  1. MacSphere
  2. Open Access Dissertations and Theses Community
  3. Open Access Dissertations and Theses
Please use this identifier to cite or link to this item: http://hdl.handle.net/11375/13801
Title: Lentiviral-Engineered Mesenchymal Stem Cells for Hemophilia B Gene Therapy
Authors: Dodd, Megan J.
Advisor: Hortelano, Gonzalo
Ofosu, Fred
Department: Biomedical Engineering
Keywords: gene therapy;hemophilia;mesenchymal stem cell;Factor IX;lentivirus;differentiation;alginate;translational;Molecular, cellular, and tissue engineering;Molecular, cellular, and tissue engineering
Publication Date: 2013
Abstract: <p>Hemophilia B patients may have frequent, spontaneous and life-threatening bleeds that are currently managed by an invasive and expensive treatment. Mesenchymal stem cells (MSCs) are increasingly being applied to clinically therapeutic strategies and lentiviral gene vectors have been shown to be safe and efficient tools for modifying stem cells for long-term expression of high levels of transgenes. In this study, MSCs were engineered with a lentivirus to express sustained and therapeutic levels of human FIX protein <em>in vitro </em>and in mice. The modified MSCs secreted human FIX protein at levels exceeding 4 μg/10<sup>6</sup> MSCs/24 h with high FIX coagulant activity of greater than 2.5 mIU/10<sup>6</sup> MSCs/24 h for 6 week <em>in vitro. </em>Functional FIX transgene was continually expressed by these cells when they were induced to differentiate into adipocyte, osteoblast and chondrocyte lineages <em>in vitro</em>. However, the modified MSCs transplanted via tail vein into NOD-SCID-γ mice expressed low levels of FIX <em>in vivo</em>. The transplantation procedure had an increased risk of death that was more pronounced in mice that received cell doses exceeding 2 million cells. Organ examinations suggested the deaths resulted from entrapment of MSCs in pulmonary capillaries. Modified MSCs encapsulated in alginate-PLL microcapsules and transplanted into the peritoneal cavity of both NOD-SCID-γ and hemophilia B mice at 9 million cells/mouse resulted in therapeutic expression around 100 ng of human FIX/mL of plasma only for a few days <em>in vivo</em> as human FIX expression quickly decreased to basal values by the end of the first week. Cultured <em>ex vivo</em>, human FIX expression by retrieved capsules indicated an innate immune response to the encapsulated cells prevented sustained expression of FIX. These investigations demonstrate that lentivirally modified MSCs have the potential to express therapeutic human FIX for sustained periods <em>in vitro</em>, even after their differentiation. However, they also highlight the challenges to overcome to optimize cell engraftment and survival following transplantation, and to minimize the immune responses associated with the xenogeneic translational<em> </em>models used.</p>
URI: http://hdl.handle.net/11375/13801
Identifier: opendissertations/8630
8832
4057350
Appears in Collections:Open Access Dissertations and Theses

Files in This Item:
File SizeFormat 
fulltext.pdf
Open Access
2.89 MBAdobe PDFView/Open
Show full item record Statistics


Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.

Sherman Centre for Digital Scholarship     McMaster University Libraries
©2022 McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4L8 | 905-525-9140 | Contact Us | Terms of Use & Privacy Policy | Feedback

Report Accessibility Issue